CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 320 target
Drug / intervention
Caspofungindrug
Likely dose
Caspofungin 70 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00388167
NCT00388167N/ACompleted
CompareCT.gov

PROCAS: Study Observational Prospective and Multicenter to Determine the Clinic Effectiveness and the Safety of Caspofungin Acetate (CANCIDAS®) in the Treatment of Invader Fungal Infection

PETHEMA Foundation·observational·Posted Oct 16, 2006·Updated May 13, 2009

In Brief

An observational study evaluating Caspofungin for Candidiasis and Aspergillosis. Completed, enrolled 320 participants across 27 sites.

Detailed Summary

We wanted to determine the efficacy and the safety of caspofungin acetate (CANCIDAS®) in the treatment of invader fungal infection (IFI) specifically, Invasive Candidiasis (CI) in adults patients without neutropenia and Invasive Aspergillosis (AI) in adults patients who are refractory to or intolerant of other therapies (i.e., amphotericin B, lipid formulations of amphotericin B, and/or itraconazole).

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsCandidiasis, Aspergillosis
CountriesSpain
CollaboratorsGTEI, SEMICYUC

Timeline

N/ACompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedOct 16, 2006
Enrollment StartMar 1, 2004
Study CompletionFeb 1, 2008
TodayJul 2, 2026
Posted 19.7 years ago

Interventions

Caspofungindrug

The patients are treated with 70 mg IV of caspofungin on day 1, followed by 50 mg/day IV during the rest of treatment